Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type JAK2 ...
Overcoming drug resistance with EAI-432, an allosteric EGFR inhibitor for non-small cell lung cancer
EAI-432, an allosteric inhibitor, offers a new approach to targeting mutant-EGFR driven NSCLC By binding outside the ATP pocket, it co-binds with the current standard-of-care third generation EGFR ...
HANGZHOU, China and SHANGHAI and BOSTON, Dec. 2, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development ...
Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program ...
TRPM5 protein helps the body sense taste, control blood sugar and defend the gut. Scientists found hidden control site in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback